Genocea Biosciences Teams with Pneumococcus Expert Richard Malley of Children's Hospital Boston/Harvard Medical School

CAMBRIDGE, Mass. & SEATTLE--(BUSINESS WIRE)--In advance of a major international symposium on pneumonia next week, Genocea Biosciences, a leading vaccine discovery and development company, today announced a research and collaboration agreement with PATH to speed the development of a new vaccine to fight Streptococcus pneumoniae. PATH is pursuing a number of approaches to develop pneumococcal vaccines that will be effective and affordable in the countries that most urgently need them. PATH, Genocea, and Richard Malley, M.D., associate professor of Pediatrics at Children’s Hospital Boston, will collaborate on a protein-subunit pneumococcal vaccine for use in the developing world. Dr. Malley is one of the world leaders in immune mechanisms of protection against pneumococcus and is also principal investigator of a 2006 PATH-supported project to develop a whole-cell pneumococcal vaccine for children in the developing world.

Back to news